SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending due to a mixed reaction to earnings, with initial positive revenue overshadowed by a one-time tax charge and concerns about increased spending on AI infrastructure. The community is debating whether the dip is a buying opportunity or a sign of deeper issues with the company's investment strategy. Some investors believe the market is overreacting, while others are wary of Meta's increasing capital expenditures.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI is trending as the community rallies around its potential, emphasizing a conviction-based approach over hype. Talk centers on the token's strong community and resilience within the $SOL ecosystem, with many expressing a shared belief that 'we're all gonna make it.'

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid anticipation for an upcoming meeting between President Trump and China's President Xi, with trade deal hopes influencing market sentiment. Community members are actively discussing potential impacts on major tech companies following mixed earnings reports from key players like Microsoft and Meta, while some express concern about an over-reliance on a few top stocks. Investors are weighing the potential for further market gains against concerns about stretched valuations and the broader economic outlook.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending due to a significant post-earnings drop, sparking discussions about reduced guidance and declining customer traffic amid macroeconomic pressures. Community members are debating the company's valuation, food quality, portion sizes, and pricing, with some suggesting it's oversold and ripe for institutional investment while others point to waning popularity. The impact of tariffs and competition from other fast-casual restaurants like CAVA are also being considered.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it surpasses a $5 trillion market cap, fueled by exceptionally strong AI chip demand and CEO Jensen Huang's forecast of $500 billion in cumulative revenue through 2026; the community is closely watching Trump's upcoming meeting with President Xi for potential easing of China's Blackwell restrictions, while also weighing the potential impact of increased capex from major tech companies like Microsoft and Meta.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending due to a significant stock drop following disappointing earnings and a lowered outlook, prompting analysts to downgrade the stock. The community is discussing potential corporate fraud, a management shakeup, and whether this presents a buying opportunity or a value trap. Some are hopeful for a quick bounce, while others are wary of deeper declines and possible investigations.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending amid ongoing speculation about a potential merger with Warner Bros. Discovery ($WBD), with discussions focusing on offer prices and deal structures. Community chatter revolves around whether a deal will materialize and its potential impact, particularly as analysts debate the value and future of the combined entity, while others point to upcoming earnings and layoffs as key events to watch.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors analyze the implications of the company's recent earnings report, particularly regarding its AI spending and Azure cloud growth. Community discussions revolve around whether the earnings justify the current valuation and forward guidance. The broader context includes Microsoft's significant stake in OpenAI and its ongoing competition in the cloud computing arena against companies like Amazon and Google.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending as traders discuss a potential short squeeze and the stock's undervaluation following recent earnings and future growth prospects. Community members are focused on potential price targets and the possibility of a buyout, while also analyzing short interest and options activity. Speculation about analyst upgrades and the impact of potential government actions are contributing to the heightened interest.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet's stock is trending as traders discuss the company's recent earnings beat and growing excitement around its AI and cloud computing initiatives. Community members are highlighting Google's AI strategy and potential for further growth, particularly compared to other tech giants. Some are also discussing the impact of Google's capital expenditure plans and partnerships in the AI space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Exact Sciences (EXAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth

Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apellis Pharmaceuticals is drawing renewed attention from short sellers even as its stock extends a rebound sparked by better-than-expected&nbsp;bottom-line results.Short interest as a percentage of free float rose to 21.1% last week, the highest in three weeks, after bottoming near 21% in late July, according to Ortex data compiled by The Fly.&nbsp;Days-to-cover climbed to 2.8 from 2.6, although volumes stayed heavy following the earnings release, limiting further upside pressure.Shares gained 13.5% in the five sessions through Thursday and have now rallied 45% since July 31, when Apellis reported a second-quarter loss of $0.33 per share, narrower than&nbsp;analysts’ expectations.&nbsp;<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> rose 0.5% on Friday to close at $27.75, its highest level in six months, extending a four-session winning streak.Revenue of $178.5 million missed consensus by about $10 million, but investors cheered the earnings surprise along with regulatory and business updates.&nbsp;Quarterly sales were driven by $151 million from Syfovre, its treatment for geographic atrophy, and $21 million from Empaveli for paroxysmal nocturnal hemoglobinuria. Apellis also secured FDA approval of Empaveli for rare kidney diseases C3G and primary IC-MPGN, the first approved therapies for these conditions.Additionally, Apellis signed a capped royalty deal with Sobi worth up to $300 million for ex-U.S. Aspaveli sales and ended June with $370 million in cash.&nbsp;The company said the combination of cash, the Sobi payment, and future revenues should be sufficient to fund operations to profitability.Following the quarterly results, Goldman Sachs&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/retail-buzz-surges-for-apellis-as-goldman-hikes-price-target-after-solid-syfovre-sales-fda-win-for-kidney-drug/chr3ZbiRdGS">raised its price target</a> to $26 from $24, citing strong quarterly execution and long-term potential across its complement-focused pipeline.&nbsp;Citi lifted its target to $46 from $41, calling Empaveli “best-in-class,” while Scotiabank raised its target to $22 on confidence in launch execution. Baird, BofA, and Morgan Stanley also issued upward revisions earlier in August, reflecting improving sentiment.Despite the rebound, the pickup in short positioning suggests some investors expect profit-taking after the momentum-driven surge.On Stocktwits, retail sentiment for Apellis&nbsp;remained ‘bearish’ amid ‘extremely low’ message volume.Apellis’ stock has declined 13% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

APLS stock has declined 13% so far in 2025. (Photo credit: Getty Images)

Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary

Apellis stock has surged since its earnings, but rising short interest suggests some investors are betting on profit-taking.

Equity

Retail chatter around Apellis Pharmaceuticals spiked Thursday after Goldman Sachs raised its price target to $26 from $24, citing strong quarterly performance and long-term growth potential through its pipeline of immune system therapies.Goldman’s move came on the heels of Apellis’ second-quarter earnings report, which showed total revenue of $178 million.&nbsp;Syfovre, the company’s treatment for geographic atrophy,&nbsp;generated $151 million in U.S. net product sales,&nbsp;representing a 6% quarter-over-quarter&nbsp;increase in injection volume. Despite a $13 million revenue impact due to increased free sample usage linked to co-pay assistance constraints, the product maintained a dominant market position with over 60% share of new GA patient starts.&nbsp;Empaveli contributed $20.8 million in sales, supported by high compliance rates.The FDA’s recent approval of Empaveli for patients aged 12 and older with C3G and IC-MPGN added another major catalyst. Backed by Phase 3 Valiant trial data, the decision cleared the way for Empaveli’s use in two rare kidney diseases that impact approximately 5,000 patients in the U.S.&nbsp;The trial showed a 68% drop in urinary protein levels, steady kidney function, and clearance of C3 deposits, which are key indicators of kidney health. The label also includes patients with post-transplant recurrence of C3G.Analyst sentiment has improved notably in recent weeks. Citi raised its price target to $46 from $41, calling Empaveli “best-in-class” and a potential growth driver. Scotiabank lifted its target to $22, highlighting confidence in the company’s ability to execute on the Empaveli launch. Baird, BofA, and Morgan Stanley also issued upward revisions earlier this month.Apellis also strengthened its balance sheet through a $300 million royalty agreement with Sobi, selling 90% of future ex-U.S. royalties on Aspaveli, the ex-U.S. brand of Empaveli, for $275 million upfront.&nbsp;The deal includes a $25 million milestone tied to potential EMA approval for the new kidney indications later this year.On Stocktwits, retail sentiment was ‘extremely bullish’ late Thursday amid a 72% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> has declined 32.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around Apellis Pharmaceuticals (APLS) spiked Thursday after Goldman Sachs raised its price target to $26 from $24. (Photo credit: Getty Images)

Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug

Goldman Sachs cited Apellis’ 6% quarterly injection growth for Syfovre and potential market upside from Empaveli’s newly approved indications in C3G and IC-MPGN, despite recent revenue headwinds from co-pay assistance constraints.

Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Repligen (RGEN) Lags Q2 Earnings Estimates

Repligen (RGEN) delivered earnings and revenue surprises of -7.50% and +3.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Retail buzz around Apellis Pharmaceuticals&nbsp;intensified on Monday after the FDA approved Empaveli,&nbsp;clearing the way for its use in treating two rare kidney diseases that often lead to kidney failure.&nbsp;The drug is now approved for patients 12 and older with C3G and IC-MPGN, which are conditions that affect 5,000 people in the U.S.&nbsp;The decision was backed by data from the Phase 3 Valiant trial, where patients on Empaveli saw a 68% drop in protein levels in their urine, a key sign of kidney stress, along with steady kidney function and signs that harmful C3 deposits were being cleared.&nbsp;The label also includes patients with post-transplant recurrence of C3G.The FDA decision comes amid a flurry of Wall Street updates on Apellis. Earlier this month, Baird raised its price target on Apellis to $50 from $47, updating its model ahead of second-quarter earnings and noting competitive developments in the C3G space.Morgan Stanley and BofA also raised their price targets, now at $26 and $24, respectively.&nbsp;BofA maintained a ‘Neutral’ rating and noted that Apellis has not provided sales guidance for Syfovre, its treatment for geographic atrophy. Morgan Stanley maintained an ‘Equal Weight’ rating and cited the royalty purchase agreement with Sobi.Apellis recently struck a $300 million royalty deal with Sobi, selling 90% of its future ex-U.S. royalties from Aspaveli, its treatment for a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), to strengthen its cash position.Apellis will receive $275 million upfront and may earn another $25 million if Aspaveli is approved for C3G and IC-MPGN in Europe.On Stocktwits, retail sentiment for Apellis was ‘extremely bullish’ amid a 2,350% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> has declined 43.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Chronic kidney disease, computer illustration and light micrograph. The illustration shows the gross anatomy of kidneys with chronic glomerulonephritis. | Image source: Getty Images

Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals 

The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial. 

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag

SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli

APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$30.05
Prev Close	$30.05
Open	$30.24
Dividend Yield	0.00%
50-Day Moving Average	$25.76
Beta	0.91
Avg. Volume	2.28M
PE Ratio	-16.48

52-Week High	$35.72
52-Week Low	$16.10
Market Capitalization	$3.8B
EPS (Annual)	-$1.60
Price to Book	24.26
Revenue Per Employee	$1.1M
Enterprise Value/EBITDA	N/A

APLS
Apellis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest APLS News

APLSApellis Pharmaceuticals Inc